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Introduction
Bl ood glucose (BG) homeostasis is maintained by a complex system involving coordinated interplay between various hormone and metabolite signals. One critical component, the endocrine pancreas, regulates glucose production and metabolism by a synchronized reciprocal release of insulin and glucagon in response to changes in BG, incretins, and other signals. Abnormal secretion and action of the pancreatic peptides play a role in the progression of many diseases, including diabetes, metabolic syndrome, polycystic ovary syndrome, and others. Diminished or complete loss of endogenous insulin secretion in diabetes is associated with failure of the pancreas to respond properly with glucagon secretion not only to hyper-but also to hypoglycemia. The latter is not caused by loss of glucagon secreting α cells, but by defects in glucagon counterregulation (GCR) signaling, through an unknown mechanism. Defective GCR is a major barrier to safe treatment of diabetes 1,2 since unopposed hypoglycemia can cause coma, seizures, or even death. 3, 4 Our experimental 5 and mathematicalmodeling [5] [6] [7] results show that a novel understanding of the defects in the GCR control mechanisms can be gained if the network of intrapancreatic interactions that control glucagon secretion is described and analyzed by a mathematical model.
We first developed 5, 6 a model of the endocrine pancreas suitable for the study of rodent physiology. Later, a new simplified construct 7 (in which δ-cell somatostatin was not explicitly involved) was also shown to closely approximate the GCR control mechanisms. This construct was applied to study the abnormalities in glucagon secretion and counterregulation and to explore in silico ways for their repair. Here, we review these efforts and highlight possible applications and extension of our models.
Construct Development
To describe the glucagon axis, we simplified the system by clustering all known and unknown factors into a small number of explicitly recognized physiological relationships chosen initially to explain key experimental results (e.g., the in vivo enhancement of GCR by switchoff of insulin). 8 The postulated network 5 included relationships between the α cells, δ cells, BG, and switchoff signals (intrapancreatically infused α-cell inhibitors that are terminated during hypoglycemia). This network explained the repair of GCR in diabetic rats by switch-off signals by interpreting the GCR as a rebound or disinhibition effect. It also predicted that (1) in β-cell deficiency, multiple α-cell suppressors should enhance GCR if they are terminated during hypoglycemia, and (2) the switch-off-triggered glucagon response must be pulsatile. We confirmed these predictions in vivo, in STZ-treated rats. 5 The construct was further extended 6 to reflect the assumption that the α-cell activity can be regulated differently by different α-cell inhibitors as suggested by earlier experiments. 5 However, the explicit involvement of somatostatin in the model limits the potential for clinical applications as pancreatic somatostatin cannot be measured reliably in humans in vivo and the ability of the model to describe the human glucagon axis cannot be verified. To address this limitation, we reduced our initial construct into a minimal control network (MCN) of the GCR control axis in which the δ cells are no longer explicitly involved but their effects are implicitly incorporated. 7 Our analyses (reviewed later) show that the MCN is an excellent model of the glucagon axis and can replace the earlier, more complex structure. It can be also tested clinically and used to predict the behavior of the human GCR axis both in β-cell sufficiency and deficiency.
Our models are based on published studies of the pancreatic peptides that as a whole suggest that a network of interacting pathways modulates the secretion of glucagon. These key relationships are summarized here and are described extensively elsewhere. [5] [6] [7] β-Cell Inhibition of α Cells 1. Blood within the islets flows from β to α to δ cells. [9] [10] [11] [12] 2. β cells secrete signals known to inhibit the α cells: insulin, zinc, GABA and amylin.
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δ-Cell Inhibition of α Cells 1. Exogenous somatostatin inhibits glucagon (and insulin). [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 2. The α and β cells express somatostatin receptors 25, 31, 32 that may mediate the inhibition of glucagon by endogenous δ-cell somatostatin. 22, 23, 32 3. The δ cells are in close proximity to α cells, and δ cell processes extend into α-cell clusters. 30, 34 α-Cell Stimulation of δ Cells 1. Blood within the islets flows from α to δ cells (mentioned earlier) and administration of glucagon antibodies in the perfused human pancreas inhibits somatostatin. 3. δ-cell somatostatin release is stimulated by glucose in vitro. 44, 45 Glucose Inhibition of α Cells
Hyperglycemia inhibits glucagon even though hypoglycemia alone may be insufficient to stimulate GCR. 16, [46] [47] [48] [49] [50] [51] Indirect evidence also supports the concept of network control of GCR: pulsatility of the pancreatic hormones; [52] [53] [54] release of insulin and somatostatin pulses in phase; 55, 56 insulin and glucagon pulses and somatostatin and glucagon pulses with a phase shift; 53 and entrainment of α-and δ-cell oscillations by insulin pulses. 57 We have shown that a network based on the relationships mentioned earlier explains key experimental findings and have presented experimental evidence to support the proposed construct. 5, 6 In particular, we have used differential equations-based modeling to show that the proposed network explains each of the following findings in diabetic rats: 6. Higher GCR response to insulin vs somatostatin switch-off and stronger glucagon suppression by somatostatin than by insulin before a switch-off. 5 Next, we have simplified the network in such a way that somatostatin is no longer explicitly involved but is incorporated implicitly. 7 This new MCN is shown in Figure 1 .
The MCN was approximated by a model consisting of two differential equations:
Here, GL(t), BG(t), and INS(t) denote time-dependent concentrations of glucagon, BG, and insulin, respectively; the derivative is the rate of change with respect to the time, t. The term Pulse in Equation (2) denotes a pulse generator specific to the β cells. The meaning of the parameters and the way they have been determined has been explained in detail 7 and the parameter values are summarized 7 in Table 1 . In brief, the half-life of glucagon and insulin was chosen to match published data, which determines the elimination constants k GL and k INS . The delay in the auto-feedback, D GL , the potencies t BG and t GL , and the sensitivities n BG and n GL in the auto-feedback function were functionally determined to guarantee glucagon pulsatility with a frequency that matches our experiments. 5 The parameters r INS , r INS,basal (secretion rates), t BG,2 (potency), n BG (sensitivity), and the amplitude of the pulse generator, Pulse, were functionally determined so that a glucose bolus drives an increase in insulin over baseline similar to that reported in the literature. The potency t INS was functionally determined so that insulin withdrawal during hypoglycemia triggers GCR. The secretion rates r GL and r GL,basal were determined so that a strong hypoglycemic stimulus can trigger more than 10-fold increase in glucagon. The parameters of the pulse generator, Pulse, were chosen to mimic published reports on insulin pulsatility in the portal vein.
To validate this model, we have demonstrated 7 that the MCN model parameters can be determined to reconstruct the mechanism of GCR and response to switch-off signals in insulin deficiency and other key experimental observations [all (1) through (4) and their approximation by the MCN. In the in vivo experiments, 5 BG was first reduced to 100-110 mg/dl, followed by a constant intrapancreatic infusion of a switch-off signal (saline, insulin, or somatostatin); blood samples were collected every 5 minutes. Ten minutes after the start of the infusion of the switch-off signal, an insulin bolus (12 U/kg) was given intravenously to induce hypoglycemia. The intrapancreatic infusion was switched off when BG fell to <60 mg/dl (switch-off point). The simulations were performed using the MCN model [Equations (1) and (2)] as described. 7 In particular, hypoglycemia was modeled by simulated gradual BG decline from 110 mg/dl (starting at t = 1 h) to BG = 60 mg/dl at the switch-off point (t = 2 h).
The plots show excellent agreement of the model predictions and the observations. Note that pulsatility of glucagon is not apparent in the top panels since they show averaged data, but was demonstrated on the individual profiles by deconvolution. 5 We have shown that the MCN approximates basic properties of the normal endocrine pancreas as well: increased insulin secretion and decreased glucagon release in response to hyperglycemia stimulation. 7 We have also demonstrated that the mechanisms underlying the dysregulation of GCR in insulin deficiency can be reconstructed by the MCN: (1) 
Model-Based Predictions
Our simulations (partially summarized in Figure 3 ) lead to several model-based predictions:
• The appearance of defects in GCR is reciprocally linked to the development of high basal glucagon secretion.
• GCR abnormalities in insulin deficiency are due both to a lack of a switch-off and to a significant intraislet hyperglucagonemia.
• Significant GCR reduction requires a severe loss of β-cell activity, consistent with clinical observations that defective GCR is accompanied with a severe loss of endogenous insulin. These predictions suggest that in β-cell deficiency, it may be possible to repair defective GCR by uninterrupted infusion of signals capable of suppressing basal hyperglucagonemia. Since this strategy is more practical than a switch-off, we tested the GCR model response to hypoglycemia assuming different modes of suppression of glucagon secretion: gradual suppression of either basal (r GL,basal ) or system-regulated/pulsatile (r GL ) glucagon, or both (Figure 4) .
The model predicts that reduction in basal glucagon leads to a significant improvement in pulsatile GCR since it of the Defects in Glucagon Counterregulation and Potential Extension to Approximate Glucagon Action in the pulsatile glucagon secretion entails consistent reduction in the GCR (Figure 4 , bottom pink curve). However, if inhibition of total (both basal and pulsatile) glucagon secretion is assumed (as one might expect during in vivo infusions of α-cell suppressors), the model predicts initial enhancement of the GCR response, followed by its gradual decline (Figure 4 , middle black curve). Maximal amplification is predicted at about 45% reduction of glucagon. (Figure 5, bottom) . This leads to two key model-based predictions:
• If an α-cell suppressing signal is administered at high doses and is not switched off, the GCR response to hypoglycemia will be suppressed.
• Lower, carefully selected infusion rates of α-cell inhibitors to partially reduce glucagon secretion may repair defective GCR in insulin-deficient diabetes.
These predictions are supported by some clinical observations [58] [59] [60] [61] and suggest strategies to manipulate the in vivo MCN to repair defective GCR in β-cell deficiency. For example, if some α-cell suppressors (GLP-1, amylin, GABA, etc.) or GLP-1 stimulators (vildagliptin) are continuously infused at clinically appropriate rates, they may restore the GCR and decrease glucagon during eu-and hyperglycemia. We also have some pilot data suggesting that uninterrupted intrapancreatic infusion of GABA can enhance GCR in STZ-treated rats (unpublished).
Further Model Verification

Additional In Vivo Verification in Rodent Models
The model-based simulations are consistent with key experimental outcomes and support the postulated MCN model. However, these simulations reconstruct only general "averaged" behavior of the in vivo system and approximate portal rather than circulating concentrations. Therefore, new experimental data are required to demonstrate further that the model approximates well the glucagon axis. These should involve interventional studies to infuse hormones and signals into the pancreas and analyze frequently glucagon and other peptide responses in portal vein blood samples. Analysis of such data by the mathematical model will evaluate whether the MCN provides an objectively good description of the action of the complex GCR control mechanism.
Relating Portal and Circulating Glucagon Concentrations: Use of a Transfer Model
The mathematical methods for analyzing the GCR control mechanisms use portal rather than peripheral venous hormone concentrations and can be easily tested in rats but not humans by experiments in which the pancreatic hormones are sampled in the portal vein. If blood samples from the portal vein cannot be collected, the methodology could be extended to reconstruct the GCR axis from peripheral venous concentrations only. Such capabilities are thus critical for the analysis of clinical data since it is not feasible to sample insulin and glucagon in the portal vein in humans.
One simple empirical way to relate the concentration of a hormone in the portal vein to the concentration of the same hormone in the general circulation is to use the following equation to describe how the rate of change of circulating glucagon (Glucagon circ ) is affected by the concentrations seen into the portal vein (Glucagon portal ).
Glucagon circ ' = -k cl Glucagon circ + V dist Glucagon portal (3) This equation accounts for delay, spread, and partial clearance of glucagon by the liver and circulation (modeled by the compound elimination parameter k cl ). The difference between the portal and general circulation distribution volumes and flow rates is accounted for by the compound parameter V dist . A similar equation Figure 5 . Changes in GCR response to hypoglycemia in (complete) insulin deficiency in response to three levels (10%, top; 40%, middle; and 80%, bottom) of α-cell suppression.
[Equation (4)], or, alternatively, one of the existing C-peptide models (e.g., see Tura and colleagues) 62 could be used to relate portal to circulating insulin. Thus, a model that can be used in analyzing data collected in the circulation consists of the original pancreatic model, Equations (1) and (2), and an additional transfer model (TM), Equations (3) and (4). In rodents, one can determine precisely the TM parameters by measuring both portal and circulating glucagon and insulin. In humans, they have to be inferred from circulating data or extrapolated from the rodent model. To illustrate that the TM can be validly combined with the original construct, we utilize data from pilot experiments where uninterrupted intrapancreatic infusion of GABA appear to enhance the pulsatile GCR response to hypoglycemia in STZ-treated rats (unpublished). The original model of the insulin-deficient pancreas [Equation (1) with INS = 0] was used to approximate the release of glucagon into the portal vein in combination with Equation (3) to relate portal vein to circulating glucagon. We determined the system parameters such that the model response to the experimentally observed decline of BG into hypoglycemia provides the best fit to the observed circulating glucagon response. Accordingly, several parameters were individualized. In Equation (1), we adjusted D GL (delay in the glucagon auto-feedback), t GL [median infective dose (ID 50 ) for glucagon as it suppresses its own release], k GL (rate of elimination of glucagon in the portal circulation), and n GL (Hill coefficient/slope of the glucagon auto-feedback action). The effect of GABA on basal glucagon secretion was estimated by fitting r GL,basal . In Equation (3) we fitted k cl and V dist . The other parameters were fixed to the previously determined values ( Table 1 ). The parameters of the GCR control mechanisms under reference conditions (GABA not infused) were determined by finding a value of r GL,basal such that the GCR response to hypoglycemia is suppressed. Figure 6 shows that the reconstructed GCR control mechanism provides an excellent description of the data: 99.07% of the variance in the experimentally observed circulating glucagon data was explained.
The figure also depicts the reconstructed portal vein glucagon (dotted green line) reaching ~13-fold higher concentrations than the levels observed in the circulation. We found that a 4-fold increase of r GL,basal blocked the GCR (Figure 6 , blue dashed line), which suggests that in this particular experiment, GABA may have exerted its GCR amplifying action by inhibiting basal glucagon ~4-fold.
Perspectives: Extension of the Model to Approximate Glucagon Action
In vivo, the interactions between pulsatile insulin and glucagon are under the regulation not only of BG but of incretins as well and their combined effects exert a network control on the hepatic glucose output (HGO) (Figure 7) .
Abnormalities in this larger network underlie the progression of many diseases, including diabetes, metabolic syndrome, and polycystic ovary syndrome. Defects of GCR might be also mediated in part by defects in the way the HGO is regulated. Hyperinsulinemia, found in many metabolic disorders, may originate from several individual or a combination of different mechanisms. Therefore, a natural future extension of our models is to approximate the network shown in Figure 7 . First, to include GLP-1, one can multiply the right-hand side terms in Equations (1) Figure 7 . Primary dose-response interactions between the pancreatic peptides, blood glucose, GLP-1, and HGO. The effect of food intake is also included in addition to other key functions critical to maintaining glucose homeostasis, which initially may be not part of the system we are considering (dotted lines). Circulating glucose is known to stimulate the release of insulin from β cells and directly or indirectly (e.g., via islet δ-cell somatostatin) to inhibit the release of glucagon from α cells. The additional pathways (as compared to Figure 1 ) are as follows: insulin inhibits HGO; 63 GLP-1 stimulates insulin and suppresses glucagon secretion; 64 glucagon stimulates the HGO 40 ; food (oral glucose) intake stimulates the release of GLP-1, 64 increases the glucose levels in the circulation, and directly suppresses the HGO.
to approximate stimulation of HGO by glucagon (GL) and its suppression by insulin (INS) and glucose (BG). Here, it is assumed that there is a basal (r GL,basal ) and a system-regulated HGO component. The parameter r HGO is related to the maximal HGO, and the right-hand upand down-regulating terms are presented as Hill functions. This extended model [Equations (1)-(4) plus the description of the HGO] can be used to simulate the system behavior, and in silico studies will determine whether and with what experimental design this extended model can be used to "measure" the parameters of the system interactions (the solid lines in Figure 7 ) in clinical applications tailored to track the progression of a disease or to estimate the effectiveness of a therapy.
Conclusions
Experimental data suggest that control of glucagon involves a complex network-like structure and this article describes our efforts to characterize mathematically and experimentally the network control of glucagon secretion and counterregulation. A streamlined model is proposed that is consistent not only with most of the in vivo system behavior typical for the insulin deficient pancreas but also explains key pathophysiology, characteristic for the transition from a normal to an insulin-deficient state. A major advantage of this streamlined model is that its only explicit components are BG, insulin, and glucagon. These are all clinically measurable, which of the Defects in Glucagon Counterregulation and Potential Extension to Approximate Glucagon Action should allow the application of the new construct to the study of the control, function, and abnormalities of the human glucagon axis. A key model-based prediction is that careful partial suppression of hyperglucagonemia may repair defective GCR in insulin-deficient diabetes. If proven correct, such an outcome will have important clinical implications.
The selected few MCN components cannot recreate (nor should they need to) all signals that control the glucagon axis, which is influenced by various extrapancreatic factors with important impact on glucagon secretion and GCR, including autonomic input, catecholamines, growth hormone, ghrelin, and incretins. 13, 58, [65] [66] [67] [68] [69] These other signals are not omitted but are unified in the MCN based on the assumption that the primary physiological relationships that are explicit in the model are influenced by these factors.
The primary application of our models is to simulate system behavior, and the reviewed in silico results suggest that they are consistent with the existing experimental data. New experiments, however, are needed to further validate the model. These should include infusions manipulating the signaling input to the pancreas combined with frequent sampling of the portal vein to better capture the corresponding changes in the pancreatic output.
Finally, our models can be modified so that concentrations of pancreatic peptides can be reconstructed from their circulating levels. This is important in the analysis of clinical data where portal sampling is impossible. They can also be part of a larger construct, showing their regulation of the hepatic glucose output by the pancreas, glucose, and incretins. It is possible that this larger model can be used in clinical applications to track the progression of a disease or of a specific therapy.
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